Question explored with the scientific record
is the nasal child flu vaccine a) effective and b) safe?
The short version: this nasal flu vaccine works modestly against flu in children, but the safety evidence is thin and the long-term picture is simply not studied.
Effectiveness is real but modest. In England in 2015-2016, the nasal vaccine cut flu hospitalizations in children by about 42% [7]. That is a genuine benefit, but it means roughly 6 in 10 hospitalized flu cases were in vaccinated children anyway. The older trials show the same pattern: the live nasal vaccine protects better than the injected one in some head-to-head comparisons, but the numbers are small and the protection is partial [2]. One Indian study claimed 76% effectiveness against lab-confirmed H1N1, but it was retrospective, not a randomized trial, and the confidence intervals were wide [6].
The safety evidence is the weak half. The largest safety dataset here is VAERS, the passive reporting system, which catches only a fraction of real adverse events by design [4]. It found 460 reports in about 2.5 million doses, including 40 serious ones: possible anaphylaxis, two confirmed cases of Guillain-Barré syndrome, Bell palsy, and febrile seizures [4]. That is not a clean bill of health. It is a system that misses most harms, finding a handful anyway. The asthma trial was tiny, 24 children per group, and still showed more asthma exacerbations in the vaccinated group, 2 versus 0, though not statistically significant [1]. The egg-allergy study was a cohort, not randomized, with 68 children [3].
What is missing matters more than what is here. No long-term safety study appears in this retrieval. No comparison of vaccinated versus truly unvaccinated children over years. The mechanism questions are unaddressed: live vaccine virus shedding was substantial in young children [5], and what that means for transmission to vulnerable contacts is not answered here. The burden of proof sits with the intervention, and this evidence does not meet it for long-term safety.
My call: the nasal vaccine offers a modest, real reduction in flu illness in children, but the safety evidence is too thin to call it clearly safe, and the long-term data simply does not exist. Confidence: low.
Sources used 7
-
Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma
A randomized, double-blind, placebo-controlled trial assessing the safety and tolerability of intranasal live attenuated CAIV-T influenza vaccine in children and adolescents with moderate to severe asthma, finding no significant adverse effects on lung function or exacerbations …
DOI: 10.1097/00006454-200201000-00010 -
ADVANTAGE OF LIVE ATTENUATED COLD-ADAPTED INFLUENZA A VIRUS OVER INACTIVATED VACCINE FOR A/WASHINGTON/80 (H3N2) WILD-TYPE VIRUS INFECTION
A randomized challenge study showing intranasal live attenuated cold-adapted influenza A (H3N2) vaccine provides substantially superior protection against wild-type A/Washington/897/80 infection and illness in young adults compared with a licensed inactivated vaccine, largely by…
DOI: 10.1016/s0140-6736(84)92222-0 -
Safe vaccination of patients with egg allergy by using live attenuated influenza vaccine
Intranasal live attenuated influenza vaccine appears safe for egg-allergic children, with no immediate anaphylaxis and only mild nonspecific adverse events within 24 hours.
DOI: 10.1016/j.jaip.2014.08.008 -
Adverse Events Reported Following Live, Cold-Adapted, Intranasal Influenza Vaccine
This study analyzes US VAERS data from 2003–2005 to characterize adverse events reported after intranasal live, attenuated influenza vaccine (LAIV-T), finding 460 reports (including 40 serious) among about 2.5 million vaccinees, with rare events such as possible anaphylaxis and …
DOI: 10.1001/jama.294.21.2720 -
Immunization of Infants and Young Children with Live Attenuated Trivalent Cold-Recombinant Influenza A H1N1, H3N2, and B Vaccine
A double-blind trial in infants and young children showing that intranasal administration of a live attenuated trivalent influenza vaccine (A/H1N1, A/H3N2, and B) is safe and immunogenic in triply seronegative recipients, but with substantial vaccine-virus shedding and varying i…
DOI: 10.1093/infdis/165.4.727 -
Effectiveness of an Indian-made Attenuated influenza A(H1N1 ) pdm 2009 vaccine
A retrospective case-control study in Pune, India evaluating the effectiveness of the Indian-made intranasal Nasovac live attenuated influenza A(H1N1)pdm 2009 vaccine, showing approximately 76% effectiveness against laboratory-confirmed H1N1 infection.
DOI: 10.4161/hv.27490 -
Influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children in England in the 2015–2016 influenza season – a test-negative case–control study
In 2015-2016 England, influenza vaccination in vaccine-eligible children 2-16 years provided 33.4% adjusted effectiveness against laboratory-confirmed influenza hospitalisation, with LAIV at 41.9% and IIV at 28.8%.
DOI: 10.1017/s0950268819000876